---
title: "Taysha Gene Therapies, Inc. (TSHA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TSHA.US.md"
symbol: "TSHA.US"
name: "Taysha Gene Therapies, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T23:17:01.506Z"
locales:
  - [en](https://longbridge.com/en/quote/TSHA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TSHA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TSHA.US.md)
---

# Taysha Gene Therapies, Inc. (TSHA.US)

## Company Overview

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.tayshagtx.com](https://www.tayshagtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.62)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 218 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.42% |  |
| Net Profit YoY | -49.69% |  |
| P/B Ratio | 7.44 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1577611999.80 |  |
| Revenue | 7471000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -97.28% | E |
| Profit Margin | -1738.40% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 3.42% | C |
| Net Profit YoY | -49.69% | D |
| Total Assets YoY | 117.08% | A |
| Net Assets YoY | 284.94% | A |
| Cash Flow Margin | 86.20% | C |
| OCF YoY | 3.42% | C |
| Turnover | 0.03 | E |
| Gearing Ratio | 29.43% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Taysha Gene Therapies, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-49.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.44",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1577611999.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7471000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-97.28%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1738.40%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "3.42%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-49.69%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "117.08%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "284.94%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "86.20%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "3.42%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "29.43%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -12.15 | 468/385 | - | - | - |
| PB | 7.44 | 369/385 | 9.46 | 5.83 | 5.06 |
| PS (TTM) | 211.16 | 272/385 | 204.05 | 168.10 | 82.91 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 77% |
| Overweight | 3 | 23% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.54 |
| Highest Target | 19.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TSHA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TSHA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TSHA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TSHA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**